TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06009159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: 30 minutes stimulation, twice per day for 4 weeks
Study: NCT05431348

Intervention type: DEVICE
Intervention: Smartwatch
Description: Patients will wear the smartwatch during treatment which measures, activity, steps, sleep and heartrate
Study: NCT05768503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug
Description: The treatment option for the chidamide + sintilimab + bevacizumab is 200 mg of sintilimab IV Drip Q3W, 30 mg of chidamide PO BIW, and bevacizumab 7.5 mg/kg IV Drip Q3W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Rx
Description: The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400 mg/m2 IV Q2W or calcium levofolinate 200 mg/m2 IV Drip Q2W, 5-fluorouracil 400 mg/m2 IV +2400 mg/m2 CIV (infusion 46-48 hr) Q2W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
Study: NCT04401007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block with 1.5% lidocaine
Description: Erector spinae plane (ESP) block is a new regional nerve block technique that involves a percutaneous injection of local anesthetic as a bolus through a needle or catheter into the fascial plane between the erector spinae muscle and the transverse processes in the upper or mid back.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block with 1.5% lidocaine
Description: Erector spinae plane (ESP) block is a new regional nerve block technique that involves a percutaneous injection of local anesthetic as a bolus through a needle or catheter into the fascial plane between the erector spinae muscle and the transverse processes in the upper or mid back.
Study: NCT06034158

Intervention type: DRUG
Group type: OTHER
Intervention: single-dose madopar, single-dose propranolol, and single-dose placebo by order
Description: Participants will take madopar, propranolol, and placebo (orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.

Intervention type: DRUG
Group type: OTHER
Intervention: single-dose madopar, single-dose placebo, and single-dose propranolol by order
Description: Participants will take madopar, placebo(orange juice), and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
Study: NCT06071871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab is given intravenously at a dose of 2.5mg over 4 hours on Cycle 1 Day 8. Patients need to stay in hospital for 24 hours.~Glofitamab is given intravenously at a dose of 10mg over 2 hours on Cycle 1 Day 15. (Patients may need to stay in hospital for 24 hours.) Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1 of Cycles 2-12 (as relevant).
Study: NCT05431348

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Cortisol
Description: Level of cortisol in serum will be determined

Intervention type: OTHER
Intervention: Questionnaires
Description: Patients are asked to fill in patient reported outcomes (PROMS) and specific questions on stress, exercise and fatigue (QSC-R23, IPAQ-SF, MVI-20)
Study: NCT05307250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE
Description: In addition to the BSOC, ALHIV and their caregivers will participate in a family strengthening intervention plus a family economic empowerment intervention.~MFG is an evidence-based family-centered, group-delivered, evidence-informed, strength-based 10-session (weekly) intervention for children whose families struggle with poverty. Six additional sessions covering HIV stigma stigma-related issues will be added.~ALHIV will receive a YDA with a 1:1 matched savings program at a financial institution accredited by the Bank of Uganda. Each YDA will be opened in the name of the adolescent, with their primary caregiver as a co-signer, until the adolescent turns 18 years. The account will then be matched with money from the program on 1:1 rate.
Study: NCT06071871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab is given intravenously at a dose of 2.5mg over 4 hours on Cycle 1 Day 8. Patients need to stay in hospital for 24 hours.~Glofitamab is given intravenously at a dose of 10mg over 2 hours on Cycle 1 Day 15. (Patients may need to stay in hospital for 24 hours.) Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1 of Cycles 2-12 (as relevant).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Polatuzumab is given intravenously at a dose of 1.8mg/kg on Cycle 1 Day 2, and then Day 1 of Cycle 2-Cycle 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Polatuzumab is given intravenously at a dose of 1.8mg/kg on Cycle 1 Day 2, and then Day 1 of Cycle 2-Cycle 6.
Study: NCT05307250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE plus Group-based stigma reduction for educators (GED-HIVSR).
Description: In addition to BSOC and MFG-HIVSR+FEE, ALHIV in this arm will receive the school-level HIV stigma reduction intervention targeting teachers, school nurses, matrons, and administrators (headteachers, director of studies) in their schools. GED-HIVSR seeks to impart educators in the intervention schools with HIV related knowledge, provide a safe space for educators to explore their personal values and bias that may promote or hinder their role of supportive individuals and systems for ALHIV, and empower them with knowledge and skills to act as change agents within their schools.

Intervention type: OTHER
Group type: OTHER
Intervention: Bolstered Standard of Care (BSOC)
Description: All participants (in control and treatment arms) will receive medical and psychosocial support as part of the BSOC. 1) Medical SOC: All public clinics, including our study sites, follow procedures for pediatric ART initiation and monitoring, as outlined in the National Department of Health Guidelines for pediatric HIV care in Uganda. Specifically, immediately after initiation, or if clinically unstable, ALHIV are seen more frequently (weekly to monthly). Laboratory data (VL and CD4 counts) are collected every six months until the patient is stabilized and then annually, using the National Health Laboratory Service standardized protocol. A
Study: NCT06071871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
Study: NCT05307250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bolstered Standard of Care (BSOC)
Description: All participants (in control and treatment arms) will receive medical and psychosocial support as part of the BSOC. 1) Medical SOC: All public clinics, including our study sites, follow procedures for pediatric ART initiation and monitoring, as outlined in the National Department of Health Guidelines for pediatric HIV care in Uganda. Specifically, immediately after initiation, or if clinically unstable, ALHIV are seen more frequently (weekly to monthly). Laboratory data (VL and CD4 counts) are collected every six months until the patient is stabilized and then annually, using the National Health Laboratory Service standardized protocol. A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bolstered Standard of Care (BSOC)
Description: All participants (in control and treatment arms) will receive medical and psychosocial support as part of the BSOC. 1) Medical SOC: All public clinics, including our study sites, follow procedures for pediatric ART initiation and monitoring, as outlined in the National Department of Health Guidelines for pediatric HIV care in Uganda. Specifically, immediately after initiation, or if clinically unstable, ALHIV are seen more frequently (weekly to monthly). Laboratory data (VL and CD4 counts) are collected every six months until the patient is stabilized and then annually, using the National Health Laboratory Service standardized protocol. A
Study: NCT06552572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab is administered to patients who have residual disease after CD19 CAR T-cell therapy for their relapsed or refractory diffuse large B-cell lymphoma
Study: NCT05653349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ianalumab
Description: Intravenous infusion, prepared from concentrate solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ianalumab
Description: Intravenous infusion, prepared from concentrate solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion, prepared from matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Oral or parental (if clinically justified)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Oral or parental (if clinically justified)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroids
Description: Oral or parental (if clinically justified)
Study: NCT05924672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA Positron Emission Tomography (PET) Scan
Description: Undergo PSMA PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc 99M Medronate
Description: Undergo MDP
Study: NCT04808427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TULSA-PRO
Description: Transurethral MR-Thermometry Guided Ultrasound Ablation of the Prostate
Study: NCT06374147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SVS mattress
Description: The intervention group will receive standard therapy plus continuous SVS stimulation using the Prapela SVS incubator pad. The control group will receive only standard therapy, using an inert pad (identical to the SVS pad, its controller, and green light, but without the transducer and therefore incapable of vibration), in order to mask caregivers. Treatment with the pad will continue until an infant is apnea-free for 3 days and \<2 weeks from anticipated discharge or at the clinician's discretion to discontinue treatment. After ending treatment, clinicians will observe patients 24 hours later and if apnea returns, should re-initiate treatment as needed. At 1 and 2 years of age, parents will be contacted for a brief telephone follow up survey to assess neurological development
Study: NCT05887674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: Low inflammatory-index diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Guided muscle strength training and stretching exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Guided muscle strength training and stretching exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training will be implemented in person

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training will be implemented in person
Study: NCT06650553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinically diagnosed AA patients are divided into HLA-matched HSCT group and umbilical cord blood-supported haplo-HSCT group.
Description: This clinical trial is divided into three stages: the screening phase, the treatment phase, and the follow-up phase. During the screening phase, patient enrollment must be completed, and baseline conditions must be recorded. In the treatment phase, the transplantation treatment process for patients in the HLA-matched HSCT group and the umbilical cord blood-supported haplo-HSCT group must be completed, and treatment conditions must be recorded. In the follow-up phase, outcome evaluation indicators must be collected according to the follow-up plan, ensuring data quality.
Study: NCT06509815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIRA
Description: The study device is a Multi-Sensory Stimulation Device named MIRA, which uses commercially available hardware and builds off the SOLUNA software created by Studio Elsewhere. The device produces audio and visual stimuli of immersive experiences. Participants in the intervention group will either have periodic or scheduled intervention sessions. The study team member will roll the MIRA device into the patient participant's room before the session and roll it out after. The intervention requires the participant to be in bed. The study team member will set up the device and start the intervention session which can last between 15-60 minutes. During the session, data will be collected by the study team member.
Study: NCT05439291

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular Epilation Regimen
Description: Epilation using laser device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular Epilation Regimen
Description: Epilation using laser device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical excision
Description: Excision of pilonidal pit with trephine
Study: NCT05925309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem
Description: Sulperazone 50mg/kg q8h is used intravenously from the first day to the 14th day after KP surgery. Ursodeoxycholic acid 20mg/kg/d p.o, starting from the 5th day after surgery for at least 2 years. Compound glycyrrhizin 20mg/d i.v, 1-4 days after operation, then switch to compound glycyrrhizin tablets 12.5mg b.i.d p.o until 6 months after KP. Methylprednisolone start at 4mg/kg/d i.v on the 8th day after operation, and decrease by 1mg/kg/d every three days. Starting at about the 15th day after operation, methylprednisolone 4mg/kg is given orally every other day, and the dose is gradually reduced at 10-12 weeks. Vitamin AD , D , E , K, are given orally from the 5th day after the KP for at least 2 months. Treatment of cholangitis: sulperazone 50mg/kg q8h i.v., and methylprednisolone could be used. If cholangitis is not controlled, imipenem or meropenem may be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem
Description: Sulperazone 50mg/kg q8h is used intravenously from the first day to the 14th day after KP surgery. Ursodeoxycholic acid 20mg/kg/d p.o, starting from the 5th day after surgery for at least 2 years. Compound glycyrrhizin 20mg/d i.v, 1-4 days after operation, then switch to compound glycyrrhizin tablets 12.5mg b.i.d p.o until 6 months after KP. Methylprednisolone start at 4mg/kg/d i.v on the 8th day after operation, and decrease by 1mg/kg/d every three days. Starting at about the 15th day after operation, methylprednisolone 4mg/kg is given orally every other day, and the dose is gradually reduced at 10-12 weeks. Vitamin AD , D , E , K, are given orally from the 5th day after the KP for at least 2 months. Treatment of cholangitis: sulperazone 50mg/kg q8h i.v., and methylprednisolone could be used. If cholangitis is not controlled, imipenem or meropenem may be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor
Description: Compound sulfamethoxazole tablet (SMZ/TMP) 25 mg/kg/d p.o. and cefaclor 12.5 mg/kg/d p.o. alternately every 2 weeks, from post-operation day 15 to month 6.
Study: NCT05146700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restrictive oxygen
Description: Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liberal oxygen
Description: 15 L O2/min flow for non-intubated trial participants or FiO2 = 1.0 for intubated trial participants in the initial phase; later in the operating room, intensive care unit, post-anesthesia care unit and ward, the flow/FiO2 can be reduced to ≥12 L O2/min or FiO2 ≥0.6 if the arterial oxygen saturation is ≥98%
Study: NCT04233788

Intervention type: DEVICE
Intervention: MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)
Description: The MR-scans performed at 3T and 7T are performed to evaluate whether high field MR-examinations bring an advantage to the patient in determining the IDH-status of the glioma. Two MRSI/CEST sequences will be tested against each other.

Intervention type: DEVICE
Intervention: MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)
Description: The MR-scans performed at 3T and 7T are performed to evaluate whether high field MR-examinations bring an advantage to the patient in determining the IDH-status of the glioma. Two MRSI/CEST sequences will be tested against each other.

Intervention type: DEVICE
Intervention: MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)
Description: The MR-scans performed at 3T and 7T are performed to evaluate whether high field MR-examinations bring an advantage to the patient in determining the IDH-status of the glioma. Two MRSI/CEST sequences will be tested against each other.
Study: NCT05138861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-03 (Lotilaner Ophthalmic Solution), 0.25%
Description: A single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 1 and then twice a day (in the morning and in the evening, approximately 12 hours apart) starting on Day 2 for 40 consecutive days (Days 2 to 41). Thereafter, a single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 42, for a total of 82 consecutive doses administered in each eye.
Study: NCT06129448

Intervention type: DIAGNOSTIC_TEST
Intervention: transthoracic echocardiography
Description: All echocardiographic studies will be performed by one physician (Merve Maze AYDEMIR) using a commercially available echocardiographic system (P4-2 probe, DC-60, Mindray, Shenzhen, China) in the back-to-top or left lateral decubitus position. All images will be digitally stored from three cardiac cycles as standard apical four-chamber and parasternal short-axis views.

Intervention type: DIAGNOSTIC_TEST
Intervention: transthoracic echocardiography
Description: All echocardiographic studies will be performed by one physician (Merve Maze AYDEMIR) using a commercially available echocardiographic system (P4-2 probe, DC-60, Mindray, Shenzhen, China) in the back-to-top or left lateral decubitus position. All images will be digitally stored from three cardiac cycles as standard apical four-chamber and parasternal short-axis views.
Study: NCT05001893

Intervention type: DEVICE
Intervention: S53P4 bioactive glass putty
Description: Bonalive putty/putty MIS paste is a synthetic, bioactive, osteoconductive, osteostimulative bone void filler for filling, reconstruction, and regeneration of bone defects.
Study: NCT04861077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FMISO-PET with contrast-enhanced MRI
Description: Triple negative breast cancer patients that are planning to undergo immunotherapy and consent to this study will have 3 imaging visits. Imaging visit 1 will take place before the patients start immunotherapy. Imaging Visit 2 will take place after the patient completes the 1st cycle of immunotherapy and before they start their 2nd cycle. Imaging Visit 3 will take place when the patient completes the 2nd cycle of immunotherapy and before they start the 4th cycle.
Study: NCT06034158

Intervention type: DRUG
Group type: OTHER
Intervention: single-dose propranolol, single-dose madopar, and single-dose placebo by order
Description: Participants will take propranolol, madopar, and placebo(orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.

Intervention type: DRUG
Group type: OTHER
Intervention: single-dose propranolol, single-dose placebo, and single-dose madopar by order
Description: Participants will take propranolol, placebo(orange juice), and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.

Intervention type: DRUG
Group type: OTHER
Intervention: single-dose placebo, single-dose propranolol, and single-dose madopar by order
Description: Participants will take placebo(orange juice), propranolol, and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.

Intervention type: DRUG
Group type: OTHER
Intervention: single-dose placebo, single-dose madopar, and single-dose propranolol by order
Description: Participants will take placebo(orange juice), madopar, and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
Study: NCT04233788

Intervention type: DEVICE
Intervention: MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)
Description: The MR-scans performed at 3T and 7T are performed to evaluate whether high field MR-examinations bring an advantage to the patient in determining the IDH-status of the glioma. Two MRSI/CEST sequences will be tested against each other.
Study: NCT06469736

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard of Care Ureterorenoscopy
Description: The patient provides written informed consent and is positioned in the supine position. After disinfection, sterile draping, and single-shot antibiotic administration a rigid cystoscopy is performed. Intubation of the ostium with a hydrophilic guidewire and placed into the renal pelvis under fluoroscopic control. After a semirigid URS, a working sheath is placed up to the Kidney. A flexible URS with lithotripsy with a Thulium lase is then performed to dust the stones. The fragments are retrieved for analysis. Finally, a double-J or mono-J stent and a transurethral catheter are placed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Ureterorenoscopy with MediNiK
Description: The patient provides written informed consent and is positioned in the supine position. After disinfection, sterile draping, and single-shot antibiotic administration a rigid cystoscopy is performed. Intubation of the ostium with a hydrophilic guidewire and placed into the renal pelvis under fluoroscopic control. After a semirigid URS, a working sheath is placed up to the Kidney. A flexible URS with lithotripsy with a Thulium lase is then performed to dust the stones. The fragments are retrieved for analysis. Application of MediNiK to embbed the residual stones in the hydrogel and extract it with a basket. Finally, a double-J or mono-J stent and a transurethral catheter are placed.